Quantitative EEG (Brain Mapping)

Aetna covers quantitative EEG (qEEG/brain mapping/BEAM) only as an adjunct to standard EEG for: ambulatory recordings to aid expert visual interpretation; continuous frequency‑trending monitoring to detect early acute intracranial complications in the OR/ICU; select cerebrovascular evaluations when imaging and routine EEG are inconclusive; and evaluation of dementia/encephalopathy unresolved after initial clinical assessment. All other uses (e.g., ADHD, depression, PTSD, concussion/sports concussion, autism spectrum disorders, Parkinson’s, chronic pain, substance use, etc.) and devices such as BrainScope One are considered experimental/investigational and not covered, and qEEG is not recommended as a screening/replacement for imaging given insufficient evidence of outcome benefit or reduced follow‑up testing.

"Chronic pain (diagnosis and guide to strategies for pain control)"